A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
Public ClinicalTrials.gov record NCT02284568. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Study identification
- NCT ID
- NCT02284568
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Enrollment
- 374 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Laquinimod Drug
Drug
Eligibility (public fields only)
- Age range
- 25 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 11, 2015
- Primary completion
- May 3, 2017
- Completion
- Sep 30, 2017
- Last update posted
- Mar 9, 2022
2015 – 2017
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 12966 | Phoenix | Arizona | 85018 | — |
| Teva Investigational Site 12967 | Newport Beach | California | 92663 | — |
| Teva Investigational Site 12962 | San Francisco | California | 94158 | — |
| Teva Investigational Site 12964 | Aurora | Colorado | 80045 | — |
| Teva Investigational Site 12973 | Northbrook | Illinois | 60062 | — |
| Teva Investigational Site 12975 | Kansas City | Kansas | 66160-7314 | — |
| Teva Investigational Site 12969 | Lenexa | Kansas | 66214 | — |
| Teva Investigational Site 12977 | Golden Valley | Minnesota | 55422 | — |
| Teva Investigational Site 13010 | Golden Valley | Minnesota | 55422 | — |
| Teva Investigational Site 12965 | Chesterfield | Missouri | 63017 | — |
| Teva Investigational Site 12968 | St Louis | Missouri | 63110 | — |
| Teva Investigational Site 12963 | New York | New York | 10016 | — |
| Teva Investigational Site 12971 | Charlotte | North Carolina | 28207 | — |
| Teva Investigational Site 12976 | Columbus | Ohio | 43221 | — |
| Teva Investigational Site 12970 | Uniontown | Ohio | 44685 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 84 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02284568, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 9, 2022 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02284568 live on ClinicalTrials.gov.